Deciphera expects to submit NDA for Vimseltinib in Q224 and MAA in Q324 in Tenosynovial Giant Cell Tumor TGCT…Results from exploratory ctDNA analysis from INTRIGUE Phase 3 study in 2L GISTpatients with mutations in KIT Exon 11+17/18 published in Nature Medicine; Final overall survival OS results from INTRIGUE study in 2L GIST patients presented at ASCO GI; Cash expected to fund operating and capital expenditures into 2H26…
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCPH: